Bonk, Inc 8-K, filed Nov 17, 2020
Bonk, Inc. (BNKK)
About this 8-K
Bonk, Inc filed this 8-K on November 17, 2020.
Items reported
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 17, 2020
JUPITER WELLNESS, INC.
(Exact name of registrant as specified in charter)
| Delaware | 001-39569 | 83-2455880 | ||
| (State or other jurisdiction | (Commission | (IRS Employer | ||
| of incorporation) | File Number) | Identification No.) |
725 N. Hwy A1A, Suite C-106 Jupiter, FL 33477
(Address of principal executive offices) (Zip Code)
(561) 244-7100
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| [ ] | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| [ ] | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| [ ] | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| [ ] | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| Common Stock | JUPW |
The Nasdaq Stock Market LLC (The Nasdaq Capital Market)
| ||
| Warrants, each exercisable for one share of Common Stock at $8.50 per share | JUPWW |
The Nasdaq Stock Market LLC (The Nasdaq Capital Market) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company [ ]
If an emerging growth company, indicate by check mart if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item 7.01 Regulation FD Disclosure
On November 17, 2020 Jupiter Wellness, Inc. issued the attached press release. A copy of the press release is attached hereto and incorporated herein by reference in its entirety as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits
Exhibits
| Exhibit No. | Description | |
| 99.1 | Press release, dated November 17, 2020 |
| 1 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 17, 2020
| JUPITER WELLNESS, INC. | ||
| By: | /s/ Brian John | |
| Brian John | ||
| Chief Executive Officer | ||
| 2 |
Jupiter Wellness’ JW-100 Enters Clinical Trial for the Treatment of Herpes
| · | Marks Jupiter’s 3rd clinical indication including eczema and burns |
| · | Study data to be used in planned IND filing with U.S. FDA |
Jupiter, FL – Accesswire - November 17, 2020 - Jupiter Wellness, Inc. (Nasdaq: JUPW), a leading developer of cannabidiol (CBD) based medical therapeutics and wellness products, today announced it has initiated an exploratory clinical study in the treatment of herpes labialis (cold sores) for its prescription topical cream candidate JW-100. This trial may be the first, to Jupiter’s knowledge, to explore and ultimately show the efficacy of a combination CBD-aspartame product in the treatment of herpes labialis.
JW-100’s dual mechanism of action and relief combines CBD’s potential ability to induce apoptosis in epithelial cells infected with Kaposi sarcoma-associated herpes virus, with aspartame’s analgesic and anti-inflammatory properties.
The double blind, placebo controlled study will recruit 40 patients diagnosed with recurrent herpes labialis infection (HSV) who had their initial infection more than one year prior. Patients will be enrolled through clinical sites in Europe and Asia. The primary endpoint of the study is the duration of the herpes labialis episode.
“We are rapidly advancing our clinical pipeline with our third indication. Herpes cold sores are common, with an estimated 48% of Americans aged 14-49 having had the HSV-1 virus. We believe JW-100 has the potential to treat and provide relief with fewer side effects than the treatments on the market today. This exploratory clinical trial is in line with a Phase I FDA study, and therefore we believe the resulting data will be a valuable addition to the Investigational New Drug (IND) application we plan to file with the FDA for advanced stage trials in the U.S.,” stated Jupiter CEO Brian John.
About Jupiter
Wellness
Jupiter Wellness, Inc. (NASDAQ: JUPW) is a leading
developer of cannabidiol (CBD) based medical therapeutics and wellness products. The Company’s clinical pipeline of prescription
CBD-enhanced skin care therapeutics address indications including eczema, burns, herpes cold sores, and skin cancer. Jupiter generates
revenues from a growing line of proprietary over-the-counter skincare products including its flagship CaniSun™ sunscreen
and other wellness brands sold through its robust distribution platform.
For additional information, please visit www.jupiterwellnessinc.com. The Company’s public filings can be found at www.Sec.gov.
Safe
Harbor Statement
To the extent any statements contained in this presentation of Jupiter Wellness, Inc. (the “Company”) contains
“forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 and the information
that are based upon beliefs of, and information currently available to, the company’s management as well as estimates and
assumptions made by the company’s management. These statements can be identified by the fact that they do not relate strictly
to historic or current facts. When used in this presentation the words “estimate,” “expect,” intend,”
believe,” plan,” “anticipate,” “projected” and other words or the negative of these terms and
similar expressions as they relate to the company or the company’s management identify forward-looking statements. Such statements
reflect the current view of the company with respect to future events and are subject to risks, uncertainties, assumptions and
other factors relating to the company’s industry, its operations and results of operations and any businesses that may be
acquired by the company. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect,
actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the
company believes that the expectations reflected in the forward-looking statements are reasonable, the company cannot guarantee
future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States,
the company does not intend to update any of the forward-looking statements to conform these statements to actual results.
Investor & Public Relations Contact Info
Phone: 561-244-7100
Email: info@jupiterwellnessinc.com